1263377-68-9Relevant academic research and scientific papers
HOMOPIPERAZINYL AND HOMOPIPERIDINYL QUINAZOLIN-4(3H)-ONE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN
-
Page/Page column 144, (2021/04/17)
The present invention relates to homopiperazinyl and homopiperidinyl quinazolin- 4(3H)-one derivatives having dual pharmacological activity towards both the α2δ subunit of the voltage-gated calcium channel and the sigma-1 (σ1) receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.
PIPERAZINYL AND PIPERIDINYL QUINAZOLIN-4(3H)-ONE DERIVATIVES HAVING ACTIVITY AGAINST PAIN
-
Page/Page column 181; 182, (2020/05/28)
The present invention relates to piperazinyl and piperidinyl quinazolin-4(3H)-one derivatives having pharmacological activity towards the (formula (I)) subunit, in particular the (formula (2)) subunit, of the voltage-gated calcium channel, in particular having dual pharmacological activity towards both the (formula (I)) subunit, in particular the (formula (2)) subunit, of the voltage-gated calcium channel and the μ-opioid receptor. The present invention also relates to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.
SUBSTITUTED QUINAZOLIN-4(3H)-ONE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN
-
Page/Page column 159; 160, (2020/05/29)
The present invention relates to substituted quinazolin-4(3H)-one derivatives having dual pharmacological activity towards both the α2??subunit, in particular the α2?-1 subunit, of the voltage-gated calcium channel and the μ-opioid receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.
MACROCYCLIC KINASE INHIBITORS
-
Page/Page column 52, (2012/06/16)
Compounds of Formula (I): wherein variables are defined herein, and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers for which FAK inhibition is beneficial.
